鵜飼　渉 (ウカイ　ワタル)

写真a

所属

医療人育成センター 統合IR部門

職名

准教授

ホームページ

http://npsy.sapmed.jp/index.cgi?page=%B8%A6%B5%E6%B3%E8%C6%B0

プロフィール

 神経幹細胞，iPS細胞を用いた，社会性認知・コミュニケーション機能障害のニューラルネット解析と，より難治性の精神疾患に対する創薬・再生医療学的アプローチの実現に向けた研究を進めています。一方，自然の力を借りて，子どもの豊かな心・思いやれる脳を育もうとするNPOや幼稚園のプロジェクトに参加しています。趣味：ランニング，剣道。
このページの先頭へ▲

学位 【 表示 ／ 非表示 】

  • 札幌医科大学   医学博士

このページの先頭へ▲

経歴 【 表示 ／ 非表示 】

  • 2014年
    　
    　

    札幌医科大学   医学部   講師

    講師

このページの先頭へ▲

研究分野 【 表示 ／ 非表示 】

  • ライフサイエンス   精神神経科学  

このページの先頭へ▲

researchmapの所属 【 表示 ／ 非表示 】

  • 札幌医科大学   医療人育成センター教育開発研究部門・医学部神経精神医学講座   准教授  

このページの先頭へ▲
 

研究キーワード 【 表示 ／ 非表示 】

  • 末梢血

  • 非定型抗精神病薬

  • 言語機能

  • 神経回路網

  • GRP78

全件表示 >>

このページの先頭へ▲

論文 【 表示 ／ 非表示 】

  • Targeting therapy for homocysteic acid in the blood represents a potential recovery treatment for cognition in Alzheimer's disease patients

    Tohru Hasegawa, Wataru Ukai

    AGING-US ( IMPACT JOURNALS LLC )  8 ( 9 ) 1838 - 1843  2016年09月  [査読有り]

    　概要を見る

    At present, we have no reliable means of recovering cognitive impairment in Alzheimer's disease (AD) patients. We hypothesized that homocysteic acid (HA) in the blood might represent one such pathogen that could be excreted into the urine. Since DHA is known to reduce circulating levels of homocysteine, and since exercise attenuates this effect, it follows that supplementation of the diet with DHA, along with increased levels of physical activity, may help to reduce cognitive impairment in AD patients. Our hypothesis was proven to be correct because memory problems in 3xTg- AD mice (a model for AD in which animals develop amyloid pathology), and in a mouse model of familial AD, were recovered following treatment with an anti-HA antibody and not by amyloid treatment. Interestingly, 3xTg-AD mice with amyloid pathology showed increased levels of HA level. This could perhaps be explained by the fact that amyloid precursor protein and/or presenilin increases calcium influx, which could then increase levels of superoxide and consequently increase levels of HA from homocysteine or methionine. Our hypothesis is also partially supported by an open clinical trial of certain dietary supplements that has shown impressive results. Also there are other treatments hypothesis which would be possible for the effective therapies, such as ribonucleoprotein therapy, a beta-secretase inhibitor treatment and the metabolic enhancement treatment.

    DOI PubMed

  • Stem cell therapy: a new approach to the treatment of refractory depression

    Yoshiyasu Kigawa, Eri Hashimoto, Wataru Ukai, Takao Ishii, Kengo Furuse, Hanako Tsujino, Tomohiro Shirasaka, Toshikazu Saito

    JOURNAL OF NEURAL TRANSMISSION ( SPRINGER WIEN )  121 ( 10 ) 1221 - 1232  2014年10月  [査読有り]

    　概要を見る

    To better understand the relationship of repeated exposure to adversity during early development as a risk factor for refractory depression, we exposed pregnant female rats to ethanol and the resulting pups to corticosterone during adolescence. A stressful forced swim test was then used to induce depression-like behavior. The adolescent rat brains were examined for the possible therapeutic benefit of a combination of sertraline, an antidepressant, and neural stem cells (NSCs) complexed with atelocollagen in relation to the level of GABAergic interneuron and synaptic protein density in different brain regions. The combined exposures of prenatal and adolescent stress resulted in a reduction in parvalbumin (PV)-positive phenotype of GABAergic interneurons and reduced postsynaptic density protein 95 (PSD-95) levels in the anterior cingulate cortex, amygdala, and hippocampus. Treatments with sertraline and NSCs reversed the reductions in PV-positive cells and PSD-95 levels. Furthermore, the combined treatment of sertraline and NSCs resulted in reduced depressive-like behaviors. These experiments underscore a potentially important role for synaptic remodeling and GABAergic interneuron genesis in the treatment of refractory depression and highlight the therapeutic potential of stem cell and pharmacological combination treatments for refractory depression.

    DOI PubMed

  • Characteristics of Attempted Suicide by Patients with Schizophrenia Compared with Those with Mood Disorders: A Case-Controlled Study in Northern Japan

    Takao Ishii, Eri Hashimoto, Wataru Ukai, Yohei Kakutani, Ryuji Sasaki, Toshikazu Saito

    PLOS ONE ( PUBLIC LIBRARY SCIENCE )  9 ( 5 ) e96272  2014年05月  [査読有り]

    　概要を見る

    Recent reports suggest a lifetime suicide risk for schizophrenia patients of approximately 5%. This figure is significantly higher than the general population suicide risk consequently, detection of those at risk is clinically important. This study was undertaken to define the characteristics of suicide attempts by schizophrenia patients compared with attempts by patients with mood disorders. All patients were diagnosed using the ICD-10 criteria. The study population comprised 65 patients with F2 disorders (schizophrenia, schizotypal and delusional disorders), i.e., "the F2 group'', and 94 patients with F3 disorders (mood disorders), i.e., "the F3 group'', who presented in the clinical setting of consultation-liaison psychiatry. The F2 group had a significantly younger mean age and significantly higher ratios of 'past/present psychiatric treatment' and 'more than 3 months interruption of psychiatric treatment'. In contrast, the ratios of 'physical disorder comorbidity', 'alcohol intake at suicide attempt' and 'suicide note left behind' were significantly higher in the F3 group. The F2 group attempted suicide by significantly more serious methods. Furthermore, 'hallucination-delusion' was the most prevalent motive in the F2 group and was the only factor that showed a significant association with the seriousness of the method of suicide attempt (OR = 3.36, 95% CI: 1.05-11.33).

    DOI PubMed

  • Consensus paper of the WFSBP task force on biological markers: Biological markers for alcoholism

    Eri Hashimoto, Peter Franz Riederer, Victor M. Hesselbrock, Michie N. Hesselbrock, Karl Mann, Wataru Ukai, Hitoshi Sohma, Florence Thibaut, Marc A. Schuckit, Toshikazu Saito

    WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY ( INFORMA HEALTHCARE )  14 ( 8 ) 549 - 564  2013年12月  [査読有り]

    　概要を見る

    Objectives. This article presents an overview of the current literature on biological markers for alcoholism, including markers associated with the pharmacological effects of alcohol and markers related to the clinical course and treatment of alcohol-related problems. Many of these studies are well known, while other studies cited are new and still being evaluated. Methods. In this paper we first describe known biomarkers of alcohol-related disorders, review their features and the problems involved in their use. We then consider future developments on biomarkers and their possible impact on the field. Results. More recent findings cited include the work on type 7 adenylcyclase (AC) polymorphism and its lower expression levels in female alcoholics. Neuroimaging studies involving biomarkers have also reported brain volume reductions of gray and white matter, including amygdala and subcortical regions in alcoholic patients, while a high association between the copy number variations (CNVs) in 6q14.1/5q13.2 and alcohol dependence has more recently been identified in genetic studies. Conclusions. In addition to their possible importance for diagnosis, biomarkers may have utility for predicting prognosis, progression of the disorder, the development of new treatments, and monitoring treatment effects. Although such findings should be verified in independent studies, the search for new biomarkers is continuing. Several potential candidate biomarkers have been found recently in blood, imaging, and genetic studies with encouraging results.

    DOI PubMed

  • Plasticity-related gene 1 is important for survival of neurons derived from rat neural stem cells

    Tomio Hashimoto, Misa Yamada, Takashi Iwai, Akiyoshi Saitoh, Eri Hashimoto, Wataru Ukai, Toshikazu Saito, Mitsuhiko Yamada

    Journal of Neuroscience Research ( 11 )  91 ( 11 ) 1402 - 1407  2013年11月  [査読有り]

    　概要を見る

    Plasticity-related gene 1 (Prg1) is a membrane-associated lipid phosphate phosphatase. In this study, we first investigated the role of Prg1 in the survival of neurons derived from rat neural stem cells (NSCs) using small interfering RNA (siRNA). Prg1 knock-down decreased the cell number. Interestingly, Prg1 knock-down increased genomic DNA fragmentation, suggesting the possible induction of apoptosis. Exogenously expressed Prg1 rescued the cells from death and restored the loss of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) activity induced with Prg1 siRNA. However, exogenously expressed mutated-Prg1 (the 253rd amino acid, histidine253, had been changed to alanine) did not rescue the cell death or restore the MTT activity. Histidine253 of Prg1 has been reported to be important for lipid phosphate phosphatase activity. These results suggest that Prg1 is important for survival of neurons through its dephosphorylation activity. © 2013 Wiley Periodicals, Inc.

    DOI PubMed

全件表示 >>

このページの先頭へ▲

Misc 【 表示 ／ 非表示 】

  • 【アルコール性臓器障害】 アルコールと脳神経疾患

    鵜飼 渉, 辻野 華子, 古瀬 研吾, 木川 昌康

    細胞 ( (株)ニュー・サイエンス社 )  47 ( 14 ) 693 - 696  2015年12月

    　概要を見る

    アルコールによる脳障害と、うつ病の病態、および抗うつ薬の作用機序との間には、BDNFや小胞体ストレス、ERK系やNRSFシグナル伝達機構の変異という共通した生物学的基盤が存在し、それが、例えば患者の抗うつ薬応答性等にも関わる分子メカニズムになっていることが推察されている。アルコールの問題が背景にある患者群では、抗うつ薬の効果が有意に低下するとの臨床報告や、SSRIの中でも、特に高いBDNF産生促進効果を有することが知られるEscitalopramが、うつ病を併存したアルコール依存症患者のアルコール摂取量や渇望の低下に有効であったとの報告が複数なされ、基礎的・臨床的にその共通病態基盤の可能性が強く示唆されている。(著者抄録)

  • 胎児期アルコール曝露と成長後のストレスを組み合わせた難治性うつ病モデルにおける神経幹細胞移植療法の有効性

    鵜飼 渉, 木川 昌康, 石井 貴男, 古瀬 研吾, 辻野 華子, 岩本 倫, 田山 真矢, 白石 将毅, 橋本 恵理, 河西 千秋, 齋藤 利和

    アルコールと医学生物学 ( (株)響文社 )  33   39 - 44  2015年03月

  • 抗うつ効果とBipolarityの診断の糸口を求めて 血小板BDNF遊離機能の個体差のメカニズム解析から

    橋本 恵理, 鵜飼 渉, 石井 貴男, 木川 昌康, 古瀬 健吾, 辻野 華子, 齋藤 利和

    精神薬療研究年報 ( (公財)先進医薬研究振興財団 )  ( 46 ) 50 - 51  2014年03月

  • 抗うつ薬関連遺伝子Prg1は神経細胞の生存維持に重要な因子である

    橋本 富男, 山田 美佐, 岩井 孝志, 斎藤 顕宜, 橋本 恵理, 鵜飼 渉, 齋藤 利和, 山田 光彦

    国立精神・神経医療研究センター精神保健研究所年報 ( (国研)国立精神・神経医療研究センター精神保健研究所 )  ( 26 ) 251 - 251  2013年09月

  • 【統合失調症の病態研究から創薬への展開】 統合失調症の脳神経回路修復 薬物・細胞コンバインド療法の可能性の検討

    鵜飼 渉, 小野 貴文, 橋本 恵理, 金田 博雄, 白坂 知彦, 五十嵐 健史, 木川 昌康, 渡邊 公彦, 吉永 敏弘, 石井 貴男, 館農 勝, 小林 清樹, 齋藤 利和

    日本生物学的精神医学会誌 ( 日本生物学的精神医学会 )  23 ( 2 ) 109 - 114  2012年06月

    DOI

全件表示 >>

このページの先頭へ▲